QuickLinks -- Click here to rapidly navigate through this document

EXHIBIT 10.52

[*]=CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

FIRST AMENDMENT TO THE

DATA TRANSFER, CLINICAL TRIAL AND MARKET SUPPLY AGREEMENT

        THIS FIRST AMENDMENT to the Data Transfer, Clinical Trial and Market
Supply Agreement (the "First Amendment"), is made effective as of the 19h day of
June, 2002 (the "Amendment Date") by and between InterMune, Inc. ("InterMune"),
a Delaware corporation, having an address at 3280 Bayshore Boulevard, Brisbane,
California 94005, USA, and Boehringer Ingelheim Austria GmbH ("BI Austria"), an
Austrian corporation, having its registered office at Dr. Boehringer-Gasse
5 - 11, A-1121 Vienna, Republic of Austria. InterMune and BI Austria may be
referred to herein each individually as a "Party" and jointly as the "Parties."

        WHEREAS, InterMune and BI Austria are parties to the Data Transfer,
Clinical Trial and Market Supply Agreement dated the 27th of January, 2000 (the
"Agreement"); and

        WHEREAS, relative to the Agreement as originally executed, InterMune and
BI Austria have agreed to increased volume and capacity commitments on the part
of each Party, and modified pricing and other terms, all as further set forth
herein, and wish to amend the Agreement to reflect such terms;

        WHEREAS, InterMune and BI Austria have commenced some additional work
and desire to contract for additional services not originally contemplated by
the Agreement. These additional services consist of certain process optimization
and development work with the objective to establish a robust, high-yield, and
large scale process for production of Actimmune drug substance suitable to meet
the increased market demand of product.

        NOW, THEREFORE, the Parties hereto agree as follows:

1.The Austrian Shilling is defined in the Agreement as "ATS" in Section 1.3 of
the Agreement. The Parties recognize that the Austrian Shilling has been
replaced by the Euro. Section 4.1 of the Agreement says that payments under the
Agreement become due in an equivalent amount of Euros instead of Austrian
Shillings once the Euro replaces the Austrian Shilling. The Parties agree that
this has happened, and that payments under the Agreement shall be in Euros from
now on. The new pricing terms being added to the Agreement by this First
Amendment are stated in Euros. The Agreement is hereby amended to add as
Section 1.18(b) the following definition:

        "EURO means a euro, which is the European unit of currency."

2.The Agreement is hereby amended to insert as Section 1.38(b) of the Agreement,
immediately following Section 1.38 of the Agreement, the following definition:

        [*]

3.The Agreement is hereby amended to insert a new Section 2.1.7 after
Section 2.1.6, as follows:

"InterMune grants BI Austria a right of first negotiation for the manufacture
for clinical and commercial supply of any [*] as follows: If InterMune pursues
the development of any [*] then prior to [*], InterMune shall notify BI Austria
in writing. If BI Austria responds in writing within [*] after any such notice
from InterMune that BI Austria wishes to negotiate with InterMune the terms upon
which BI Austria would be willing to manufacture and supply exclusively to
InterMune, and InterMune would be willing to purchase from BI Austria,
quantities of such product as clinical and commercial supply, then the Parties
shall negotiate in good faith such terms for a period of not less than [*] If
the Parties do not reach agreement and execute a written agreement setting

1

--------------------------------------------------------------------------------

forth such terms during such time period, then InterMune shall have no further
obligation to BI Austria with respect to the manufacture and supply [*]."

4.The Agreement is hereby amended to delete in its entirety the second (2nd)
paragraph of Section 3.2.1 and replace such paragraph with the following:

"Following BI Austria's and BI Pharma KG's FDA approval to manufacture PRODUCT
for market supply, InterMune shall order the requested amounts of PRODUCT. In
any case the [*]

5.The Agreement is hereby amended to insert a new Section 3.2.6 after
Section 3.2.5, as follows:

"3.2.6    If InterMune determines that [*] vials of PRODUCT per year exceeds
InterMune's annual requirements for PRODUCT, then InterMune may so notify BI
Austria, stating the number of vials of PRODUCT that InterMune predicts it will
actually require going forward from the date of InterMune's notice (the "Revised
Level"). If InterMune provides BI Austria with such a notice, then:

        3.2.6.1    InterMune shall purchase (in due course on the timeline
otherwise provided for hereunder) the quantities for delivery in the [*]
quarters of the then-current forecast pursuant to Section 3.2.1 then in effect.
In such event, the [*] quarters of such forecast shall also become binding so
that all costs for PRODUCT ordered for delivery in the [*] quarters fall due and
have to be paid by InterMune; (for the avoidance of doubt, the amounts forecast
for such [*] shall [*] as the [*] in accordance with Section 3.2.3); also for
the avoidance of doubt, InterMune shall also purchase from BI Austria any
quantities of PRODUCT delivered in accordance with any purchase order hereunder
in effect at the time of InterMune's notice.

        3.2.6.2    And, the Parties shall negotiate in good faith (a) any
adjustments to the financial terms of this Agreement that may be required to
reflect [*] associated with [*] rather than on the scale of [*] vials per year,
and (b) a [*] on the part of BI Austria pursuant to Section [*] Such [*] at the
[*] may include a [*] to [*] to manufacture PRODUCT at the scale of [*] vials
per year, which [*] cannot be [*] if not [*] PRODUCT for InterMune at the
Revised Level. Such [*] shall be subject to audit by an independent accountant
[*] to BI Austria concurrently with the negotiations."

6.The Agreement is hereby amended to delete Section 3.3.4 is in its entirety and
replace it with the following:

"InterMune shall be obligated to buy and BI Austria shall be obligated to sell
only the quantities of PRODUCT which are subject to a purchase order accepted by
BI Austria; provided that BI Austria shall accept sufficient purchase orders
from InterMune annually to meet its obligations pursuant to Section 3.6.2 and in
accordance with the rolling forecast model pursuant to Section 3.2.1. Any
purchase order (or portion thereof) for which InterMune has not received a
written rejection from BI Austria within [*] of BI Austria's receipt of such
purchase order shall be deemed accepted by BI Austria."

7.The Agreement is hereby amended to delete Section 3.6.2 in its entirety and
replace it with the following:

"BI Austria guarantees to have reserved the capacity to manufacture, and to have
manufactured at BI Pharma KG (i) a minimum of [*] vials per year through
calendar year [*] ; (ii) a minimum of [*] vials per year [*]; and (iii) a
minimum of [*] vials in each calendar year thereafter during the term of this
Agreement. Such vials may be packaged and labeled for market supply, or
unpackaged and/or unlabeled for clinical supply, as requested by InterMune in
its purchase orders therefore. InterMune presumes that the amount of vials
requested per year might exceed such minimum number of vials in the years in
which such minimums apply as set forth above. Should it become at any time
apparent that InterMune requires a greater quantity of PRODUCT than the minimum
required of BI Austria as set forth above for any particular year, InterMune
will notify BI Austria thereof. BI Austria shall inform as soon as reasonably
possible InterMune [*] vials for the

2

--------------------------------------------------------------------------------

applicable calendar year. The Parties acknowledge that a lead time of up to [*]
years may be required [*] to manufacture [*] . Upon agreement on the costs and
lead time BI Austria shall reserve the capacity needed for the increased demand
of PRODUCT.

Should it become at any time apparent that it would not be feasible for BI
Austria to provide manufacturing capacity at BI Austria for [*] (i) equivalent
to [*] vials, during any calendar year [*]; (ii) equivalent to [*] vials per
year, [*]; or (iii) equivalent to at least [*] vials per year, during any
calendar year after [*], BI Austria will notify InterMune thereof."

8.The Agreement is hereby amended to insert a new Section 2.2.8. after
Section 2.2.7, as follows:

"Development and Scale-up of the MANUFACTURING PROCESS. The Parties decided to
conduct a development program to develop a robust, high-yield, and large scale
process for production of BBS (1.11) suitable to meet the increased market
demand of PRODUCT. The Parties decided to conduct such a program as additional
services under this Agreement, but the [*] in this Agreement as originally
executed. As of the Amendment Date (as defined in the First Amendment to this
Agreement), the Parties have commenced and have plans to continue certain
additional services, and have agreed upon the financial terms and work plans for
such additional services. All such additional services that have been agreed
upon by the Parties as of the Amendment Date are listed in Appendix D to this
First Amendment and shall be carried out by the Parties in accordance with the
work plan referenced in Exhibit D. All costs arising out of such additional
services shall be paid in accordance with the respective payment schedule as
also listed in Appendix D to this First Amendment. If the Parties plan and agree
upon new process development projects pursuant to this Agreement beyond that
which is agreed upon on the Amendment Date, they will exchange written plans for
such work and the financial terms, if any, therefor, prior to commencing the
work."

9.The Agreement is hereby amended to delete the number "2006" in Section 13.1
and replace it with the number [*]10.The Agreement is hereby amended to delete
in its entirety Section 14.4 and replace it with the following:

"Notices

        Any notice required or permitted to be given hereunder by either Party
shall be in writing and shall be (i) delivered personally, (ii) sent by
registered mail, return receipt requested, postage prepaid or (iii) delivered by
facsimile and confirmed by certified or registered mail to the addresses or
facsimile numbers set forth below:

If to InterMune:
 
InterMune, Inc.
3280 Bayshore Boulevard
Brisbane, CA 94005 USA
Facsimile:    +1 - 415 - 466 - 2340
Attention:    Peter Van Vlasselaer
with a copy to:
 
InterMune, Inc.
3280 Bayshore Boulevard
Brisbane, CA 94005 USA
Facsimile:    +1 - 415 - 508 - 0006
Attention:    General Counsel
 
 
 

3

--------------------------------------------------------------------------------

If to BI Austria:
 
Boehringer Ingelheim Austria GmbH
Dr. Boehringer-Gasse 5 - 11
A-1121 Vienna, Republic of Austria
Facsimile: +43 - 1-801 05 - 2440
Attention: Monika Henninger
Corporate Division Biopharmaceuticals
with a copy to:
 
Business Support Biotech
Boehringer Ingelheim GmbH
Binger Strasse 173
D-55 216 Ingelheim am Rhein
Facsimile:    +49 - 61 32 77 - 98 287
Attention:    Rolf G. Werner

11.The Agreement is hereby amended to delete in their entireties Exhibit 8, and
replace it with the replacement exhibit appended hereto as Appendix B to apply
going forward from the Amendment Date. The Agreement is hereby amended to
provide an Appendix C, to apply to pricing for PRODUCT delivered under the
Agreement on or after [*]. All references in the Agreement to Exhibit 17 shall
be deemed to refer to Appendix C whenever relating to PRODUCT delivered on or
after [*]. The prices for PRODUCT delivered [*] continue to be as set forth in
Exhibit 17 to the Agreement. The Agreement is hereby amended by a new
Appendix D, listing all additional services to be carried out by BI Austria and
the corresponding payment schedule. 12.The Table of Contents attached to this
First Amendment as Appendix A is hereby appended to the Agreement. 13.The
miscellaneous provisions included in the Agreement in Article 14 shall govern
this First Amendment in the same way that they govern the Agreement. 14.This
First Amendment amends the terms of the Agreement. Except as stated in this
First Amendment, the Agreement remains in full force and effect.

In Witness Whereof, the Parties hereto have caused this First Amendment to be
executed by their duly authorized representatives as of the Amendment Date.

Vienna, Austria   Brisbane, California

BOEHRINGER INGELHEIM
 
INTERMUNE, Inc.
AUSTRIA GmbH
 
 
 
By:
/s/  KURT KONOPITZKY      

--------------------------------------------------------------------------------

 
By:
/s/  W. SCOTT HARKONEN      

--------------------------------------------------------------------------------

Name:
Dr. Kurt Konopitzky
 
Name:
Scott Harkonen, MD
Title:
Head of Biopharmaceutical Operations
 
Title:
Chief Executive Officer
Date:
19 June 2002
 
Date:
19 June 2002
By:
/s/  PROF WERNER      

--------------------------------------------------------------------------------

 
By:
/s/  PETER VAN VLASSELAER      

--------------------------------------------------------------------------------

Name:
Prof. Dr. Rolf G. Werner
 
Name:
Peter Van Vlasselaer, Ph.D.
Title:
Head of Corporate Division Biopharmaceuticals
 
Title:
Sen. Vice President Techn. Operations
Date:
19 June 2002
 
Date:
19 June 2002

4

--------------------------------------------------------------------------------

APPENDIX TO FIRST AMENDMENT continued
dated 11 June, 2002

1.   DEFINITIONS   2     1.1   AFFILIATE   2     1.2   APPROVAL   2     1.3  
ATS   3     1.4   BI AUSTRIA'S IMPROVEMENTS   3     1.5   BI AUSTRIA'S
TECHNOLOGY   3     1.6   BI TERRITORY   3     1.7   BII   3     1.8   BI PHARMA
KG   3     1.9   BI PRODUCT   3     1.10   BLA   3     1.11   BULK BIOLOGICAL
SUBSTANCE (BBS)   3     1.12   BULK SPECIFICATIONS   4     1.13   cGMP   4    
1.14   CMC   4     1.15   COA   4     1.16   COC   4     1.17   CONFIDENTIAL
INFORMATION   4     1.18   CONTROLLED   4     1.18(b)   EURO   See First
Amendment     1.19   FDA   4     1.20   FD&C ACT   5     1.21   FILLING SITE
CHANGE   5     1.22   FINAL RELEASE   5     1.23   GENENTECH PRODUCT   5    
1.24   Genentech Technology   5     1.25   HEALTH AUTHORITIES   5     1.26  
INFORMATION   5     1.27   INTERFERON-GAMMA l b   5     1.28   INTERMUNE'S
Technology   6     1.29   MCB   6     1.30   MANUFACTURING PROCESS   6     1.31
  Material Supply Breach   6     1.32   PRODUCT   6     1.33   PROJECT MANAGER  
6     1.34   PRODUCT SPECIFICATIONS   6

i

--------------------------------------------------------------------------------

    1.35   PROJECT TEAM   6     1.36   QUALITY ASSURANCE REQUIREMENTS   7    
1.37   RELEASE   7     1.38   SERVICES   7     [*]                 1.39  
STEERING COMMITTEE   7     1.40   TERRITORY   7     1.41   US   7 2.   DATA
TRANSFER AND PRODUCT COMPARISON   8     2.1   InterMune's Tasks and
Responsibilities   8         2.1.1   Documentation   8         2.1.2   Material
  8         2.1.3   Data   8         2.1.4   Support   8         2.1.5   Contact
with HEALTH AUTHORITIES   9         2.1.6   Shipment of Material by InterMune  
9     2.2   BI Austria's Tasks and Responsibilities   10         2.2.1  
Comparison of Documentation and Materials   10         2.2.2   Production Runs  
10         2.2.3   Additional Runs   10         2.2.4   Additional Documentation
  10         2.2.5   Regulatory Support   11         2.2.6   Format and Content
of Documents   11         2.2.7   Standard of Performance   12 3.   MANUFACTURE
AND SUPPLY   12     3.1   General   12     3.2   Forecasts   13     3.3  
Purchase Orders   15     3.4   Shipment of PRODUCT and Material by BI Austria  
15     3.5   Testing and Rejection   16     3.6   Increase of Manufacturing
Capacity   17     3.7   Second Source Manufacturer   18     3.8   Material
SUPPLY BREACH   19 4.   PRICES AND PAYMENT   20 5.   QUALITY ASSURANCE AND
COMPLIANCE WITH LAW   21     5.1   Release of Product   21     5.2   Storage of
Records and Batch Samples   22     5.3   Final Release   23

ii

--------------------------------------------------------------------------------

    5.4   Third Party Services   23     5.5   Consent to Changes   23     5.6  
Inspections by HEALTH AUTHORITIES   23     5.7   Audits by InterMune   25    
5.8   Manufacturing Facilities   26     5.9   Compliance with Law   26     5.10
  Environmental   26 6.   CO-OPERATION AND CO-ORDINATION BETWEEN THE PARTIES  
27     6.1   PROJECT TEAM   27     6.2   Steering Committee   28     6.3  
Limitation of Powers   29 7.   INTELLECTUAL PROPERTY AND LICENSES   29     7.6  
New Indications   30 8.   COMPLAINTS; ADVERSE EVENTS; RECALLS   31     8.4  
Insurance   31 9.   REPRESENTATIONS AND WARRANTIES   32 10.   INDEMNIFICATION  
34 11.   LIMITATIONS ON LIABILITY   35 12.   CONFIDENTIALITY   36 13.   DURATION
AND TERMINATION   37     13.1   Duration   37     13.2   Early Termination   37
    13.3   Effect of Termination   38 14.   MISCELLANEOUS   39     14.1  
Performance by Affiliates   39     14.2   Force Majeure   40     14.3  
Assignment   40     14.4   Notices   41     14.5   Dispute Resolution; Governing
Law   42     14.6   Independent Contractor   42     14.7   Waiver   42     14.8
  Severability   43     14.9   Entire Agreement   43     14.10   Headings   43  
  14.11   Ambiguities   43     14.12   Counterparts   43     14.13   English
Language   43

iii

--------------------------------------------------------------------------------

APPENDIX B TO FIRST AMENDMENT continued
dated 11 June, 2002

Appendix B replaces EXHIBIT 8 to the Agreement

Project Manager and Project Team:

BI Austria and BI Pharma KG

Project Manager:
 
Dr. Monika Henninger, Business Support Biotech
Project Team:
 
[*]
 
 
[*]
 
 
[*]
 
 
[*]
 
 
[*]
 
 
[*]
InterMune
 
 
Project Manager:
 
Peter Van Vlasselaer, Ph.D., Senior VP Technical Operations
Project Team:
 
Staci Ellis, Associate Director Regulatory
 
 
[*]
 
 
[*]
 
 
[*]

i

--------------------------------------------------------------------------------

APPENDIX C TO FIRST AMENDMENT

Appendix C replaces EXHIBIT 17 of the Agreement

Prices and Price Adjustments

[*]

[*]

--------------------------------------------------------------------------------

  [*]

--------------------------------------------------------------------------------

  [*]

--------------------------------------------------------------------------------

[*]

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

[*]   [*]   [*]   [*]
[*]
 
[*]
 
[*]
 
[*]
[*]
 
[*]
 
[*]
 
[*]
[*]
 
[*]
 
[*]
 
[*]
[*]
 
[*]
 
[*]
 
[*]

[*]

[*]

[*]

 

 
[*]

--------------------------------------------------------------------------------

[*]   [*]
[*]
 
[*]

[*]

[*]

i

--------------------------------------------------------------------------------

APPENDIX D TO FIRST AMENDMENT continued
dated 11 June, 2002

In the technical protocols [*], the Parties have exchanged a work plan setting
forth the development work to which they have agreed (the "Work Plan"). [*] for
the work under the Work Plan are as set forth below in this Appendix D.

Actimmune—Process development and scale up

To be described in written protocols approved by the Parties

Activity

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

[*]   [*]
[*]
 
 
[*]
 
[*]
[*]
 
[*]
[*]
 
 
[*]
 
[*]
[*]
 
 
[*]
 
[*]
[*]
 
[*]
[*]
 
[*]
[*]
 
[*]
[*]
 
 
[*]
 
[*]

[*]

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

 
[*]

--------------------------------------------------------------------------------

[*]   [*]   [*]
[*]
 
[*]
 
[*]
[*]
 
 
 
[*]

i

--------------------------------------------------------------------------------

QuickLinks

FIRST AMENDMENT TO THE DATA TRANSFER, CLINICAL TRIAL AND MARKET SUPPLY AGREEMENT
APPENDIX TO FIRST AMENDMENT continued dated 11 June, 2002
APPENDIX B TO FIRST AMENDMENT continued dated 11 June, 2002
APPENDIX C TO FIRST AMENDMENT
APPENDIX D TO FIRST AMENDMENT continued dated 11 June, 2002